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  Approximately half of colorectal cancers are driven by activating mutations in KRas 
which confer resistance to standard therapies.  Ras signalling originates from transient 
nanoscale compartmentalized regions of the plasma membrane composed of specific 
proteins and lipids.  The highly specific lipid composition of these nanodomains, termed 
nanoclusters, facilitates effector recruitment, and therefore influences signal transduction.  
This suggests that Ras nanocluster proteolipid composition could represent a novel target for 
future chemoprevention interventions.  There is evidence that the consumption of fish oil, 
containing long-chain n-3 polyunsaturated fatty acids (n-3 PUFA) such as eicosapentaenoic 
acid (EPA, 20:5Δ5,8,11,14,17) and docosahexaenoic acid (DHA, 22:6Δ4,7,10,13,16,19),  may reduce colon 
cancer risk in humans, however the mechanism underlying this effect is unknown.  We 
demonstrate that dietary n-3 PUFA, via their physical incorporation into plasma membrane 
phospholipids, reduce the lateral segregation of cholesterol-dependent and independent 
nanoclusters, and suppress phosphatidic acid-dependent oncogenic KRas effector 
interactions. This results in the attenuation of oncogenic Ras-driven colonic 
hyperproliferation in both Drosophila and murine models. These findings demonstrate the 
unique properties of dietary n-3 PUFA in the shaping of Ras nanoscale proteolipid 










 Approximately 45% of colorectal cancers (CRCs) harbor KRas mutations1, which confer 
resistance to standard therapy2.  Moreover, to date, targeting of mutant Ras proteins in 
cancers has not been possible3.  A number of Ras effector proteins and cell signaling 
pathways have been defined, including the Raf and the MAP kinase pathway, the PI3K and 
the Akt/mTOR pathway, and the RalGDS and Ral pathway.  Ras effector proteins 
physically associate with Ras proteins to propagate signal transduction4.  These signals 
result in increased proliferation, decreased apoptosis, disrupted cellular metabolism, and 
increased angiogenesis, all seminal hallmarks of cancer5.  Thus, there is a critical need to 
develop new KRas targeted therapeutic approaches with reduced toxicities in the setting of 
acute or chronic administration. 
 
 High fidelity signaling of KRas is dependent on its spatial organization into defined 
proteolipid nanoassemblies6. Recently, it was demonstrated that select amphiphilic agents, 
through direct modulation of the biophysical properties of the plasma membrane, 
compromise oncogenic KRas mediated signal transduction by altering its precise nanoscale 
membrane organization7.  Furthermore, the paradoxical activation of MAPK signaling by  
BRaf inhibitors in oncogenic KRas expressing cells is driven by an increase in KRas 
nanoassembly clustering8.  These findings suggest that Ras nanoscale proteolipid 
composition could be a novel therapeutic target8.   
 
 The molecular mechanisms that influence the formation and structure of Ras 
nanoclusters involve lipid-lipid and protein-lipid interactions between the C-terminal plasma 
membrane anchor and plasma membrane phospholipids9. In regard to membrane 
phospholipids, recent work has shown that nanocluster formation is not only dependent on 
the charged head groups10, but also the asymmetry and saturation index of the fatty acyl 
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lipid tail region11.  Interestingly, dietary consumption of long-chain n-3 polyunsaturated fatty 
acids (n-3 PUFA), such as eicosapentaenoic acid (EPA, 20:5Δ5,8,11,14,17) and docosahexaenoic 
acid (DHA, 22:6Δ4,7,10,13,16,19), results in the incorporation of these fatty acids into cell membrane 
phospholipids12. This is noteworthy because the consumption of EPA and DHA may reduce 
colon cancer risk in humans13.  Hence, establishing a causal role of n-3 PUFA in colon 
cancer prevention would have a major translational impact because these dietary nutrients 
are relatively inexpensive, safe and well tolerated14.  However, the molecular mechanisms 
by which n-3 PUFA specifically impact oncogenic KRas-driven colon cancer remain to be 
determined.  Herein, we report that the incorporation of DHA and EPA into plasma membrane 
phospholipids (i) modifies KRas nanoscale proteolipid composition, (ii) disrupts oncogenic KRas 
driven signaling (pERK), and (iii) suppresses KRas associated phenotypes (hyperproliferation) 
in vitro and in vivo.  Together, these results suggest a unique role for n-3 PUFA in the 


























Material and Methods 
Mouse genetics, husbandry and diet. 
 The animal use protocol was approved by the University Animal Care Committee of Texas 
A&M University and conformed to NIH guidelines.  To generate an inducible colonic targeted 
oncogenic KRas mouse model, CDX2P-CreERT2 mice (RRID:IMSR_JAX:022390) were 
crossed with LSL-K-ras G12D mice (RRID:IMSR_JAX:008179). Mice were housed in cages in a 
temperature- and humidity-controlled animal facility with a 12 h light/dark cycle and fed lab 
chow.   
 
 For in vivo diet studies, mice were fed experimental diets containing either n-6 (control) or n-
3 PUFA for two weeks prior to tamoxifen injection (Figure 1A). Both diets contained 20% (w/w) 
casein, 42% sucrose, 22% cornstarch, 6% cellulose, 3.5% AIN-76 mineral mix, 1% AIN-76 
vitamin mix, 0.3% methionine, 0.2% choline, and 0.02% tert-Butylhydroquinone (TBHQ). The n-
6 diet contained 5% (w/w) corn oil (Dyets, Bethlehem, PA, #401150), and the n-3 diet contained 
4% menhaden fish oil (Omega Pure, Houston, TX) and 1% corn oil. The diets were changed 
daily and contained TBHQ in order to prevent peroxidation. Four weeks prior to termination, 
mice were injected once intraperitoneally (i.p.) with 200 mg/kg tamoxifen (Sigma-Aldrich, # 
T5648)15 dissolved in corn oil (as a carrier) or injected with corn oil alone. 
 
In Vivo Measurement of Crypt Proliferation and Length 
 For the purpose of measuring rates of colonic cell proliferation, mice were injected i.p. with 
50 mg/kg EdU (Life Technologies, #A10044) 2 h prior to termination. At the time of euthanasia, 
colon tissue was flushed with PBS and the colon was processed to generate Swiss rolls16. 
Swiss rolls were subsequently fixed in 4% paraformaldehyde and embedded in paraffin.  For 
cell proliferation assays, formalin-fixed paraffin-embedded 4 μm colon Swiss roll sections were 
deparaffinized and rehydrated through graded ethanol washes. Cell proliferation in colonic 
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crypts was measured using the Click-iT EdU Alexa Fluor 555 Imaging kit (Life Technologies, 
#C10338) as per the manufacturer’s instructions16.  Negative control slides were incubated 
without Alexa Fluor.   
 
 For crypt length, tissue sections were stained with Alcian blue and imaged with a Leica 
Aperio CS2 digital pathology scanner. Crypt measurement was performed using ImageScope 
(RRID:SCR_014311) software.  
 
Cell Culture 
 Conditionally immortalized Young Adult Mouse Colonic (YAMC) cells (RRID:CVCL_6E40) 
were originally obtained from R.H. Whitehead, Ludwig Cancer Institute (Melbourne, Australia).  
YAMC cells (passages 14–20) were cultured under permissive conditions, 33°C and 5% CO2 in 
RPMI 1640 media (Mediatech, Manassas, VA) supplemented with 5% fetal bovine serum (FBS; 
Hyclone, Logan, UT), 2 mM GlutaMax (Gibco, Grand Island, NY), 5 μg/mL insulin, 5 μg/ml 
transferrin, 5 ng/ml selenious acid (Collaborative Biomedical Products, Bedford, MA), and 5 
IU/mL of murine interferon- (Roche, Mannheim, Germany). YAMC cells were authenticated 
(07/24/15) by STR profiling (CellCheck Plus) by IDEXX BioResearch (Westbrook, Maine). 
Isogenic SW48 KRas (G12D/+) cells (RRID:CVCL_LC92) were obtained (10/08/14) from 
Horizon Discovery (Cambridge, United Kingdom), where they were authenticated by gDNA and 
cDNA genotyping. SW48 cells (passages 8-13) were maintained at 37°C and 5% CO2 in 
McCoy’s 5A medium supplemented with 10% FBS.  DKOB8 cells were acquired (09/19/03) from 
Dr. Patrick Casey (Duke University) who maintained them for Dr. Gideon Bollag, Onyx-
Pharmaceuticals (San Francisco, California)17. DKOB8 cells (passages 7-12) were maintained 
at 37°C and 5% CO2 in Dulbecco’s Modified Eagle Medium, high glucose medium 
supplemented with 5% FBS. Where indicated, DKOB8 cells were incubated with 10 μM 
ponasterone A (ThermoFisher, H10101) for 48 h, which verifies the cell type by large induction 
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of KRas.  All cell lines used tested negative for mycoplasma bacteria (09/15/16) as assessed by 
a MycoAlert PLUS Mycoplasma Detection Kit (Lonza, #LT07-701). Select cultures were treated 
for 72 h with 50 μM fatty acid [linoleic acid (LA, 18:2n6), arachidonic acid (AA, 20:4n6), 
eicosapentaenoic acid (EPA, 20:5n3) or docosahexaenoic acid (DHA, 22:6n3); NuChek, 
Elysian, MN] complexed with fatty acid free bovine serum albumin (BSA). 
 
Drosophila genetics, stocks, and culture.  
 The following strains were obtained from the Bloomington Drosophila Stock Center: 
w1118, UAS-RasV12 (BDSC Cat# 64196, RRID:BDSC_64196), and tub-Gal80ts (DGGR Cat# 
130454, RRID:DGGR_130454). esg-Gal4 was kindly provided by Dr. Shigeo Hayashi, Riken 
Center for Developmental Biology. UAS-GFP-tK, UAS-RFP-tK, UAS-GFP-tH, UAS-RFP-tH 
were kindly provided by Dr. John F. Hancock, University of Texas Health Science Center - 
Houston18.  All flies were reared on Bloomington’s standard medium at 25°C and 65% 
humidity on a 12h light/dark cycle, unless otherwise indicated. Newly emerged flies were 
transferred into vials with the test diets and maintained for 5 days.  
 
Drosophila Holidic Diet 
A holidic diet was prepared as previously described19. Briefly, individual diet components 
were mixed and prepared in a gel form with agar.  Once the diet cooled to < 60ºC, corn oil 
(1.79% w/w) or fish oil (1.79% w/w) along with TBHQ (0.02% w/w) was added and the diet was 
vigorously shaken to ensure uniform mixing, prior to decanting into plastic feeding tubes.  The 
fatty acid composition of the diets is described in Supplemental Table 4.  Newly emerged adult 
female flies were transferred to diets for 5 days prior to dissection and the collection of their 
guts for lipid profiling and imaging.  Dietary fish oil was well tolerated, which is consistent with 
previous studies, demonstrating that dietary long-chain fatty acids are tolerated and readily 




Conditional Expression of UAS-Linked Transgenes 
The esgGal4 driver was combined with a ubiquitously expressed temperature-sensitive 
Gal80 inhibitor (tubGal80ts).  The escargot construct drives expression in stem cells using the 
EGFR-Ras axis to maintain stemness and suppress differentiation22.  Crosses and flies were 
kept at 18°C (permissive temperature) and 5-day-old females were fed the test diets 5 days and 
then shifted to 29°C for 2 days to allow expression of the transgenes before analysis.  
 
Drosophila Immunostaining and Microscopy 
Intact fly guts were fixed at room temperature for 20 min in 100 mM glutamic acid, 25 mM 
KCl, 20 mM MgSO4, 4 mM sodium phosphate, 1 mM MgCl2, and 4% formaldehyde. All 
subsequent incubations were performed using PBS, 0.5% BSA, 0.1% Triton X-100 at 4°C. The 
following primary antibodies were used: anti-phospho-Histone H3 (Millipore; 1:1000), anti-
armadillo (1:250 dilution), obtained from the Developmental Studies Hybridoma Bank. 
Fluorescent secondary antibodies were obtained from Jackson ImmunoResearch. Hoechst dye 
was used to stain DNA. Confocal images were collected using a Nikon Eclipse Ti confocal 
system and processed using Nikon software and Adobe Photoshop. 
 
Cell Line Immunofluorescence 
 For quantitative phospho-ERK analysis, cells were seeded in cell imaging 8 chamber 
coverglass slides (Eppendorf, 0030742036) and treated with select fatty acids (50 µM) for 72 h. 
Cells were subsequently serum starved (0% FBS) for 18 h in the presence of fatty acid, 
stimulated with EGF (25 ng/ml) (PeproTech, 315-09) for 5 min and immediately fixed in ice cold 
100% methanol.  Cells were incubated with primary phosphor-ERK (Cell Signaling Technology, 
#4370, 1:200, RRID:AB_2315112) antibody followed by alexa-647 fluorescent secondary 
antibody (Jackson ImmunoResearch Labs, #711-605-152, 1:400, RRID:AB_2492288). 
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CellMaskTM Green Plasma Membrane Stain (ThermoFisher, #C37608, 1:1000) was used to 
label the cells and Hoechst 33342 (ThermoFisher, #H3570, 1:2000) to label the nucleus.  Cells 
were imaged with a 1.3 numerical aperture 40x Plan-Fluor oil objective or 1.4 numerical 
aperture 100x Plan-Apo oil objective mounted on a wide field Nikon Eclipse microscope using 
identical settings between samples.  For analysis, images were opened in NIH ImageJ software 
(ImageJ, RRID:SCR_003070; Fiji, RRID:SCR_002285), converted to Tiff files and a custom 
macro was used to quantify average fluorescent intensity of pERK.  Briefly, green membrane 
stain was used to define a binary cell mask that was applied to pERK images.  Average 
fluorescent intensity of the mask images was subsequently recorded (Supplemental Figure 3).   
 
 For quantitative nuclear pERK to cytoplasmic ratio analysis, images were captured with a 
1.15 numerical aperture 40x ACS-Apo oil objective mounted on a Leica DMi8 TCS SPE spectral 
confocal microscope. After the nuclei were highlighted by Hoechst 33342 (ThermoFisher, 
#H3570), NIH ImageJ software (ImageJ, RRID:SCR_003070; Fiji, RRID:SCR_002285) was 
used to manually define the cytoplasm and nuclear fields of interest.  Average intensities were 
used to quantify the nuclear to cytoplasm ratio. 
 
Western Blot Analysis of Intestinal Proteins 
For DKOB8 cell Western blotting, cells were homogenized in ice-cold homogenization buffer 
(50 mM Tris-HCl, pH 7.2, 250 mM sucrose, 2 mM EDTA, 1 mM EGTA, 50 mM sodium fluoride, 
1%Triton X-100, Halt Phosphatase Inhibitor Cocktail (ThermoFisher, #78420), Protease Inhibitor 
Cocktail (Sigma, #P8340), and 10 mM β-mercaptoethanol.  Following homogenization, lysates 
were sheared using a 29G needle, incubated on ice for 30 min, and centrifuged at 16,000 x g for 
20 min.  The supernatant was collected and protein concentration was assessed using 
Coomassie Plus Protein assay (Pierce, #23236).  For each sample, 10 µg of protein lysate was 
treated with 4X Laemmli Sample Buffer (Bio-Rad, #161-0747) and subjected to SDS 
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polyacrylamide gel electrophoresis (PAGE) in precast 4–20% Mini-PROTEAN TXG Stain-Free 
Gels (Bio-Rad, #456-8096).  After electrophoresis, total protein was activated and visualized 
with a ChemiDoc Imaging system (Bio-Rad, #17001401) according to manufactures 
instructions. Subsequently, proteins were electroblotted onto a nitrocellulose membrane with the 
use of a Trans-Blot Turbo Transfer Pack (Bio-Rad, #1704158) and Trans-Blot Turbo Transfer 
System (Bio-Rad, #1704150) according to manufacturer’s instructions. Following transfer, total 
protein was visualized and the membrane was incubated in Membrane Blocking Solution 
(ThermoFisher, #000105) at room temperature for 1 h with shaking, followed by incubation with 
shaking overnight at 4oC with primary antibody diluted in Membrane Blocking Solution.  
Membranes were washed with 0.1% Tween 20 in TBS (TBST) and incubated with secondary 
peroxidase conjugated secondary antibody as per manufacturer’s instructions.  Bands were 
developed using Clarity Western ECL substrate (Bio-Rad, #170-5060).  Blots were visualized 
using a ChemiDoc Imaging System.  Antibodies directed against phospho-ERK (Cell Signaling 
Technology, #4370; 1:2,000, RRID:AB_2315112), total ERK (Cell Signaling Technology, #4695; 
1:1,000, RRID:AB_390779), and Pan-Ras (MilliporeSigma, #OP40; 1:1,000 dilution, 
RRID:AB_213400) were used.  Peroxidase conjugated antibodies goat anti-rabbit IgG 
(Kirkegaard and Perry Laboratories, #074-1516; 1:20,000) and peroxidase conjugated goat anti-
mouse IgG (Kirkegaard and Perry Laboratories, #074-1806; 1:20,000) were used.   
 
For Drosophila western experiments, intact female guts were dissected in cold PBS and 
proteins extracted in Laemmli buffer, separated on 10% acrylamide gel and transferred 
according to standard procedures. Antibodies directed against phospho-ERK (Cell Signaling 
Technology, #4370; 1:1,000), total ERK (Cell Signaling Technology, #4695; 1:1,000), β-actin 
(Cell Signaling Technology; 1:5,000 dilution, RRID:AB_10950489) were used. Total protein 




Fluorescence lifetime imaging microscopy combined with fluorescence resonance 
energy transfer (FLIM-FRET). 
 For in vitro FLIM experiments, YAMC cells were seeded at a density of 1x104 in cell 
imaging 8 chamber coverglass (Eppendorf, 0030742036) 24 h prior to fatty acid-BSA (50 µM) 
treatment. Following a 24 h incubation period, media without fatty acid was added and 
Lipofectamine 3000 (ThermoFisher, #L3000-008) was used to transiently transfect cells with 
plasmids of donor (GFP-tagged protein) alone or co-transfected with FRET acceptors7,18. FRET 
acceptors were RFP-tagged proteins of interest (GFP-: RFP-plasmid at 1:3 ratio, 0.25 µg total 
plasmid per well). After 8 h in transfection media, cells were gently washed with PBS and 
incubated with complete media plus fatty acids for 40 h.  Subsequently, cells expressing GFP-
tagged protein alone or co-expressing both GFP-tagged and RFP-tagged proteins were washed 
with PBS and fixed in 4% PFA for 15 min.  After three washes in 1X PBS, HPBS was added to 
wells. The GFP fluorescence lifetime was measured using a Lambert Instrument (Roden, The 
Netherlands) FLIM unit attached to a wide field Nikon Eclipse microscope. GFP was sinusoidally 
excited by a modulating 3-Watt 497 nm light-emitting diode (LED) at 40 MHz under epi-
illumination. A solution of fluorescein (1 µM) was used as a lifetime reference standard. Cells 
were imaged with a 1.3 numerical aperture 40x Plan-Fluor oil objective using an appropriate 
GFP filter set.  The phase and modulation were determined from 12 phase settings using the 
manufacturer's software. This analysis results in an image where the fluorescence lifetime of 
GFP is determined and assigned to each pixel. The color scale on each pixel represents the 
fluorescent lifetime, which equates to the level of interaction between the GFP and RFP tagged 
proteins. Lifetime (phase) values were pooled and averaged from regions of interest drawn on 
individual cells. Each experiment was replicated at least 2 times.  Statistical analysis was 
performed using one-way ANOVA. The FLIM-FRET method is highly favored over intensity 
based FRET measurements because fluorescent lifetime is an intrinsic property of the 
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fluorescent molecule and is generally insensitive to weak signal, excitation source, and 
variations in the donor-acceptor ratio23.  
 
 For Drosophila FLIM experiments, adult flies expressing GFP/RFP constructs in gut stem 
cells were dissected in PBS and fixed 20 min in 4% PFA prior to mounting in Mowiol medium.  
Fields of view were scanned with an inverted LSM 780 microscope (Carl Zeiss Microimaging, 
Thornwood, NY) and a 1.4 numerical aperture 40× Plan Apochromat oil objective.  Two-photon 
excitation was provided by a Chameleon (Coherent Inc.) Ti:sapphire laser tuned to 900 nm. 
Emission events were registered with FastFLIM system (ISS, Champaign, IL).  Fluorescence 
lifetime images (256 × 256 pixels) were acquired with a pixel dwell time of 6.3 µs.  Lifetime of 
the imaged samples was determined with the frequency domain technique using the ISS 
VistaVision Suite version 4.1.  At least 10 images were collected per treatment.   
 
 The percentage of the apparent FRET efficiency (Eapp) was calculated using the measured 
lifetimes of each donor-acceptor pair (τDA) and the average lifetime of the donor only (τD) 
samples.  The formula employed was Eapp = (1-τDA/ τD) x 100%
24.  
 
Lipid extraction and fatty acid analysis 
For assessment of dietary lipid incorporation into membrane phospholipids, total lipids were 
extracted from isolated mouse crypts25 and at least 28 dissected Drosophila guts per treatment 
with 2:1 (v/v) chloroform-methanol as previously described26. Total phospholipids were 
subsequently separated by thin-layer chromatography with 90:8:1:0.8 (v/v/v/v) chloroform-
methanol-acetic acid-water.  After transesterification using methanolic HCl, fatty acid methyl 





 18:0-18:1 phosphatidic acid (#840861, 10 mg/mL in chloroform) and 18:0-18:1 
phosphatidylserine (#840039, 10 mg/mL in chloroform) were obtained from Avanti Polar Lipids, 
dried under nitrogen gas, resuspended in 10 mM in 150 mM NaCl and 10 mM Tris·HCl, pH 8, 




























Dietary n-3 PUFA ameliorate oncogenic KRasG12D mediated colonic phenotypes in 
vivo.  
We previously demonstrated that n-3 PUFA suppress intestinal wild type Ras activation 
both in vitro and in vivo, by upstream disruption of epidermal growth factor receptor (EGFR) 
function25,27.  However, oncogenic Ras contains a mutation that essentially keeps it in the 
active GTP-bound state1, which renders it insensitive to upstream EGFR inhibition by anti-
EGFR therapies3.  To determine if dietary n-3 PUFA can suppress oncogenic Ras mediated 
colonic phenotypes, we utilized an inducible genetic model of oncogenic KRas driven colonic 
hyperproliferation targeted to the colon15 (Figures 1A).  Following tamoxifen injection, Cre-
mediated recombination targeted to the epithelium of the distal ileum, cecum, colon and 
rectum removes transcriptional stop elements, resulting in expression of the mutant KRas 
allele under the control of its endogenous regulatory elements15.  Mice were fed a diet 
containing corn (n-6 PUFA control) or fish oil, containing EPA and DHA (Supplemental 
Tables 1 & 2) for 2 weeks prior to tamoxifen induction of oncogenic KRas, and maintained for 
an additional 4 weeks (Figure 1A).  Corn oil contains linoleic acid (LA, 18:2Δ9,12) which serves 
as a control for the non-specific effects of PUFA.  The fish oil dose is comparable to a diet 
containing approximately 8.6 g/day n-3 PUFA in humans28.  We have previously demonstrated 
that this dose is well tolerated and mice exhibit no signs of toxicity25.  As expected, mice fed a 
diet containing n-3 PUFA exhibited an enrichment of EPA and DHA in membrane 
phospholipids (Figure 1B and Supplemental Table 3).  Dietary n-3 PUFA treatment 
substantially reduced the colonic hyperproliferation induced by oncogenic KRas, as indicated 
by the significant (P<0.05) reduction of crypt length (Figures 1C & E) and number of EdU 
positive proliferative cells per crypt (Figures 1D & F). Collectively, these findings demonstrate 
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that dietary fish oil containing EPA and DHA can attenuate oncogenic KRas driven colonic 
phenotypes in vivo.  
 
Long chain n-3 PUFA reshape plasma membrane nanoscale organization of cholesterol 
dependent and independent nanoclusters.   
  Previous experiments conducted by our lab using immuno-gold electron microscopy of 
plasma membrane sheets suggest that plasma membrane organization of inner leaflets is 
fundamentally altered by EPA and DHA29,30.  Specifically, n-3 PUFA treatment altered the 
nanoscale organization of cholesterol-dependent (tH) and cholesterol independent (tK) 
probes expressed in cervical adenocarcinoma (HeLa) and colorectal carcinoma (HCT-116) 
cells29,30. These probes are composed of a fluorescent tag attached to the minimal membrane 
anchor of HRas (tH-GFP) or KRas (tK-RFP), which targets them to their respective membrane 
domains31.  In the present study, we monitored the nanoscale organization of cholesterol 
sensitive (tH) and insensitive (tK) probes by fluorescence lifetime imaging combined with 
fluorescence resonance energy transfer (FLIM-FRET) microscopy9.  When co-expressed with 
a corresponding FRET pair, such as RFP, a reduction of GFP lifetime is indicative of more 
extensive FRET as a result of a smaller distance between GFP and RFP, which is correlated 
with more extensive nanoclustering (Figure 2A).  Lifetime values were then converted to 
apparent FRET efficiency %, where an increase is indicative of enhanced nanoclustering24.   
Importantly, transient expression of these probes faithfully reports on their fraction in 
nanoclusters, as this remains constant over a multi-log range of expression levels6.  To 
explore the effects of n-3 PUFA on cholesterol-dependent and independent nanoclustering, 
we utilized immortalized young adult mouse colonocyte (YAMC) cells, which express wild type 
Ras.  This model faithfully recapitulates n-3 PUFA in vivo effects25,27,32 and allows for lipidomic 
and proteomic studies under well-controlled conditions33.  Cells were treated with a 
physiologically relevant level (50 µM)34 of albumin-complexed n-3 PUFA (EPA, DHA) or 
16 
 
control long-chain n-6 PUFA linoleic acid (LA) for 72 h. BSA-complexed fatty acids were used 
to represent the non-esterified fatty acids that are bound to albumin in vivo.  We have 
previously demonstrated that this dose is well tolerated and cells exhibit no signs of toxicity32.  
In addition, mevastatin, an HMG-CoA inhibitor was used as a positive control to reduce 
nanoclustering of Ras and FRET efficiency by blocking farnesylation and thus membrane 
anchorage of Ras24.  Interestingly, n-3 PUFA significantly increased (P<0.05) the clustering of 
tK-GFP (Figures 2B & C) while tH-GFP (Figures 2D & E) clustering was reduced (P<0.05) 
compared to untreated control.  Since a reduction in FRET can result from disruption of Ras 
membrane nanoclustering as well as loss of membrane attachment24, it is noteworthy that the 
plasma membrane association of tH-GFP but not tK-GFP is reduced following n-3 PUFA 
treatment33.   
  
 n-3 PUFA are known to modulate differences in membrane rigidity between cholesterol-
rich functional microdomains (lipid raft) and non-raft domains35, thus we sought to determine if 
EPA and/or DHA could alter the lateral segregation of normally spatially separated 
cholesterol-dependent (tH-GFP) and independent (tK-GFP) nanoclusters. This outcome would 
result in the formation of mixed heterotypic nanoclusters, as observed with certain 
nonsteroidal anti-inflammatory drugs7.  Interestingly, EPA and DHA significantly increased 
(P<0.05) the formation of heterotypic clustering, as did LA to a lesser extent (Figures 2F & 
G).  Since the precise nanoscale organization of the minimal membrane anchor of KRas does 
not completely reflect the localization of its full length oncogenic constitutively activated 
counterpart31,36, we performed similar heteroclustering experiments with the clinically relevant 
full-length form of oncogenic KRas.  Our results show that EPA and DHA significantly 
increased the formation of full length oncogenic KRas and truncated HRas heteroclusters.  In 
contrast, the n-6 PUFA control (LA) had no significant effect (Figures 2H & I).  Taken 
together, these data demonstrate that the incorporation of n-3 PUFA into plasma membrane 
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phospholipids reshapes the nanoscale organization of cholesterol-dependent and 
independent nanoclusters, contributing to the generation of mixed nanoclusters of proteins 
that are normally segregated and spatially distinct.  
  
Long chain n-3 PUFA attenuate oncogenic KRas mediated ERK signaling. 
 We next determined the functional consequences of n-3 PUFA induced nanoscale 
reorganization of the plasma membrane by examining oncogenic Ras-dependent signaling.  
For this purpose we utilized a human colon cancer SW48 cell line expressing mutated KRas.  
To limit the confounding effects associated with over-expression of oncogenic Ras37, these 
cells were designed to express one copy of the mutated KRas variant G12D from the 
endogenous KRas locus.  This particular KRas variant was chosen because one third of 
colorectal tumors harbor KRas mutations and ~80% of these mutations are at codon 12, while 
the remaining mutations are at codon 1338.  Since physiological expression of oncogenic 
KRas does not result in large increases in phosphorylation of ERK, we opted to stimulate cells 
with EGF37.  Incubation with EPA and DHA in comparison to untreated control reduced 
(P<0.05) EGF induced ERK phosphorylation by ~21 and 33%, respectively (Figures 3A & B).  
In contrast, the n-6 PUFA control (LA) had no effect compared to untreated control (Figure 
3B).  
 
 To ensure that the observed effect of n-3 PUFA reducing pERK levels was directly caused 
by disruption of Ras signaling and not an upstream modulator such as EGFR27, we utilized an 
oncogenic KRas inducible cell line, DKOB8.  These cells were generated by replacing the 
original mutated KRas allele in DLD-1 cells with a mutated KRasG12D allele under the control 
of the ecdysone-inducible vector system17.  This system allows for conditional expression of 
oncogenic KRas in the presence of ponasterone A, an analog of the insect steroid ecdysone 
(Supplemental Figure 1).  Cells incubated with ponasterone A with and without fatty acid 
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treatment exhibited an increase in pERK in the DKOB8 KRasG12D overexpression model as 
determined by immunofluorescence (Figures 3C & D) and western blot (Supplemental 
Figure 1).  Since translocation of pERK from the cytoplasm to the nucleus is required for 
mitogen induced cell proliferation39,40, in complementary experiments, ERK activation and 
location was assessed by determining the ratio of active pERK in the nucleus vs the 
cytoplasm using quantitative immunofluorescence (Figure 3E).  DHA and EPA reduced 
(P<0.05) oncogenic KRas driven nuclear pERK accumulation in the DKOB8 model as 
compared to untreated and n-6 PUFA treated (LA) cells (Figure 3E & F). 
 
Dietary n-3 PUFA reshape the nanoscale organization of sterol-dependent and 
independent nanoclusters and suppress oncogenic Ras-mediated hyperproliferation in 
Drosophila intestinal stem cells.   
 It is widely reported that a disconnect can occur between cell culture and in vivo systems.  
This is an especially challenging problem in the fields of cancer biology and nutrition, where 
complex cellular interactions govern the phenotypic outcome.  To resolve this inconsistency, we 
further examined the membrane altering properties of n-3 PUFA on functional phenotypic and 
mechanistic Ras clustering outcomes in vivo.  For this purpose, we utilized the Drosophila 
intestinal (midgut) epithelium model. The presence of somatic intestinal stem cells (ISCs) within 
the fly midgut allows for the use of a wide range of genetic tools to assay signalling events 
that govern proliferative homeostasis in vivo41.  This barrier epithelia, with functional and 
morphological similarities to the mammalian small intestine and mouse airway epithelia41, 
contains ISCs that can asymmetrically divide, forming an enteroblast (EB) that directly 
differentiates into functional enterocytes (Figure 4A). Thus, the Drosophila ISC lineage 
provides an excellent model to study signaling mechanisms regulating stem cell maintenance 




 Initially, to extend our findings in YAMC cells, we assessed the effects of a fish oil-enriched 
diet containing n-3 PUFA on sterol-dependent and independent nanoclusters in Drosophila 
utilizing transgenic flies that express Ras FRET pair constructs (UAS-GFP/RFP-truncated KRas 
and/or UAS-GFP/RFP-truncated HRas)18 specifically within ISCs/EBs (using the EsgGal4 
driver). Similar to previous in vitro cell culture experiments, control flies expressing only the 
UAS-GFP-truncated KRas/esgGal4 stem cell driver (lacking the FRET pair; establishes baseline 
lifetime of GFP with no FRET interaction) or UAS-GFP/RFP-truncated HRas/esgGal4 (used to 
comparatively determine treatment effects on clustering of truncated HRas) were also 
assessed. Flies were fed a chemically defined holidic diet19 that allowed for precise control 
over all ingredients.  The experimental diet differed from the control diet only in its lipid profile 
– fish oil at 1.79% (w/w) (Supplemental Table 4).  Phospholipid analysis of the midgut 
indicated that EPA, and to a lesser extent DHA, was enriched in flies feeding on the n-3 
PUFA-enriched diet (Table 1).  Utilizing these dietary and genetic conditions, we then 
performed FLIM-FRET to monitor truncated H- and KRas nanoclustering in Drosophila 
intestinal stem cells/enteroblasts. Consistent with our in vitro nanoclustering data (Figures 
2B-G), flies on the fish oil diet had increased tK clustering, reduced tH clustering and 
increased formation of heterotypic clustering (Figure 4B-E).  In a complementary set of 
experiments, flies were fed an additional n-6 PUFA control diet containing equal amounts of 
lipid (corn oil) (Supplemental Table 4).  This resulted in a dramatic increase in LA-containing 
phospholipids (Supplemental Table 5), however no effect on tK or tH clustering was 
observed (Supplemental Figure 2).  Finally, we examined the effect of dietary n-3 PUFA on 
oncogenic Ras-mediated phenotypes originating from stem cells in the Drosophila midgut.  
For this purpose, the expression of oncogenic RasV12 was targeted to ISCs in the adult fly, 
which leads to stem cell hyperproliferation and intestinal dysplasia (Figure 4F)42.  Flies fed n-
3 PUFA vs control exhibited a reduction in stem cell hyperproliferation, luminal 
thickening/tissue dysplasia (Figures 4F-G) and ERK activation (Figure 4H).  Collectively, 
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these data demonstrate that dietary fish oil results in the incorporation of n-3 PUFA into 
plasma membrane phospholipids in Drosophila midguts, which is associated with the 
reshaping of sterol-dependent and independent nanoclusters, and the amelioration of 
oncogenic Ras-dependent signaling and hyperproliferation in vivo.   
 
Long chain n-3 PUFA modify oncogenic KRas proteolipid nanoassembly composition. 
 We next sought to determine the mechanism by which n-3 PUFA disrupt cholesterol- 
dependent and independent lateral segregation resulting in a reduction in ERK signaling.  
Since recruitment of the effector Raf to active Ras proteolipid assemblies is a requirement of 
the RAS/ERK signal cascade, this effector recruitment can be monitored by co-expression of 
full length activated KRasG12V with the Ras-binding domain (RBD) of the effector C-Raf6.  
Similar to previous experiments, YAMC cells were treated with PUFA (50 µM) for 72 h.  EPA 
and DHA reduced the FRET signal between full length active KRasG12V and the RBD, while 
LA had no effect compared to untreated control (Figure 5A & B). The dose-dependent effect 
of DHA on the suppression of Raf effector recruitment is shown in Figure 5C &D.  
 
 Raf effectors contain lipid binding domains that drive interactions with specific lipids, such 
as phosphatidylserine (PS) and phosphatidic acid (PA)43,44.  Active KRas proteolipid 
complexes concentrate specific lipids (PA & PS) and segregate others (cholesterol) in order to 
facilitate efficient effector recruitment and therefore signal transduction9,36,45,46.  Thus, we 
assessed the effects of n-3 PUFA on the lipid composition of oncogenic KRas proteolipid 
assemblies using FLIM-FRET in YAMC cells transiently co-expressing full length activated 
KRasG12V and fluorescently tagged lipid binding domains for PS (LactC2-RFP) or PA 
(Spo20-RFP).  None of the fatty acid treatments tested had an effect on the interaction of PS 
with KRasG12V (Figure 5E & F).  In contrast, EPA and DHA reduced the interaction of PA 
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with KRasG12V (Figure 5G & H).  Importantly, addition of exogenous PA but not PS to DHA 
treated cells restored oncogenic KRasG12V-mediated RBD recruitment (Figure 5I).  
  
 KRasG12V is typically not localized to cholesterol-rich domains, as these domains are 
suboptimal for Raf activation36,46.  Thus, it is noteworthy that DHA increased the association of 
KRasG12V with the cholesterol marker D4H (Figure 5J & K).  These data suggest that DHA 
treatment mislocalizes activated KRasG12V into a cholesterol-rich domain, which likely 
contains inactivated H-Ras (Figure 2I).  Furthermore, in DHA treated cells, exogenous PA 
restored the lateral segregation of KRasG12V away from the cholesterol marker D4H, while 
PS only partially rescued the structural organization of the membrane (Figure 5K).  
Interestingly, incubation of DHA treated cells with either PA or PS failed to restore the lateral 
segregation of KRasG12V and the cholesterol-dependent tH domain (Figure 5L). These 
observations indicate that membrane enrichment of DHA results in the redistribution of PA in 
the plasma membrane inner leaflet, which in turn disrupts the nanoscale organization and 
function of oncogenic KRas proteolipid signaling complexes.  





















 Here we provide evidence that a diet containing long chain n-3 PUFA, e.g., EPA and DHA, 
attenuates oncogenic Ras signaling and phenotype (hyperproliferation) by altering its 
nanoscale proteolipid interactions at the plasma membrane (Figure 6).  To our knowledge, 
this is the first in vivo evidence that dietary bioactives can fundamentally alter Ras membrane 
nanoscale organization and signaling in the intestine.  This is highly relevant since no curative 
treatments for KRas-driven cancer are available.  From a translational and feasibility 
perspective, these findings lay the foundation for the development of toxicologically innocuous 
KRas therapeutic approaches.  Our data suggest that membrane therapy as a strategy likely 
requires the long term shaping of cellular phospholipids and hence their resident proteins28.  
The use of a prolonged regimen as a therapeutic strategy would ideally need to exhibit little or 
no adverse effects.  From a human dose perspective, EPA and DHA administration as high as 
17.6 g/day has been shown to be safe and well tolerated47.  
 
 The plasma membrane contains exquisitely organized and compartmentalized signaling 
domains, composed of lipids and proteins.  A combination of complex biophysical (electrostatic 
and hydrophobic) interactions between multiple lipid species and membrane proteins, drive the 
formation of these transient signaling domains48.  With regard to Ras, the highly specific lipid 
and protein composition of these domains allows selective recruitment of effectors, and 
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therefore is necessary to maintain efficient signal transduction49.  With respect to diet, it has 
been previously demonstrated that the incorporation of long chain n-3 PUFA into phospholipids 
can affect the biophysical properties of the plasma membrane50.  Here we extend previous 
studies focusing on membrane biophysical properties, by addressing the impact of n-3 PUFA on 
the nanoscale localization of lipids and Ras proteins.  The lateral segregation and coalescence 
of Ras proteolipid complexes is likely driven by similar biophysical properties that govern the 
phase separation of lipids observed in model membranes51.   Additionally, the ratios of 
cholesterol and sphingomyelin influence phase separation51. This is relevant because dietary n-
3 PUFA reduces colonic caveolae cholesterol25 and T-cell lipid raft sphingomyelin content26.  
Furthermore, long chain n-3 PUFA stabilizes phase separation of membranes generated in 
silico and in cell culture35,52.  This effect of n-3 PUFA on phase separation is in part dependent 
on its mol% enrichment in the membrane52.  Therefore, the mol% enrichment of n-3 PUFA in 
plasma membrane phospholipids is critical to our mechanistic hypothesis. The dose of n-3 
PUFA used in our mouse studies is a human equivalent dose of approximately 8.6 g/day, based 
on body surface area53.  Thus, the mol% enrichment of total n-3 PUFA observed in both our 
mouse and Drosophila models (Figure 1B and Table 1) is physiologically attainable in 
humans47.  These studies suggest that the biophysical effects of n-3 PUFA on the plasma 
membrane may contribute to alterations in Ras lateral segregation in human subjects.   
  
 The spatial organization of Ras isoforms into non-overlapping nanometer scale domains on 
the plasma membrane facilitates the recruitment of Raf leading to ERK activation6, thus creating 
a novel drug target8.  We observed that long chain n-3 PUFA selectively generate mixed 
cholesterol-dependent (tH-GFP) and independent (tK-GFP) nanoclusters (Figure 2G and 
Figure 4E).  This result is similar to the ability of nonsteroidal anti-inflammatory drugs7 or actin 
disruption10 to generate heterotypic mixed clusters. Interestingly, DHA is known to affect actin 
dynamics32,50,54, which may partially explain the mechanism underlying the formation of 
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heterotypic clusters.  Furthermore, the lipid composition of caveolae, which also regulates Ras 
lateral segregation55, is modified by long chain n-3 PUFA25.  Select phospholipid pools such as 
PS, PA, and phosphatidylinositol-4,5-bisphosphate (PIP2) are key structural components of Ras 
nanoclusters9,10, and the lateral segregation and heterotypic mixing of H- and KRas is 
dependent on PS levels in the plasma membrane10.  Interestingly, we have previously 
demonstrated that dietary fish oil results in the incorporation of EPA and DHA into the acyl 
chains of PS and to a lesser extent PIP2
25,26,54.  This is noteworthy, because KRas plasma 
membrane localization and nanoclustering requires specific PS acyl chain species11, raising the 
possibility that the altered PS acyl chain profile generated by dietary fish oil may underlie its 
effects on Ras nanoclustering. 
 
 The recruitment of Raf to KRas nanoclusters requires the acidic lipids PA and PS43,44.  We 
demonstrate that n-3 PUFA mislocalizes activated KRas to membrane microdomains depleted 
of PA (Figure 5H).  Notably, the mislocalized KRas predominantly associates with cholesterol-
rich domains (Figure 5K) containing truncated HRas (Figure 2I).  Cholesterol-rich regions of 
the membrane are suboptimal for Raf activation36,46, therefore these perturbations result in the 
failed recruitment of Raf to activated KRas proteolipid assemblies (Figure 5B & C) and the 
attenuation of ERK signaling (Figure 3 and Figure 4H).  Importantly, PA mediated signaling is 
required for the nuclear activation of ERK40.  Interestingly, exogenous supplementation of PA to 
DHA treated cells restores KRasG12V and cholesterol lateral segregation (Figure 5K), and Raf 
recruitment (Figure 5I), without restoring KRasG12V and tH segregation (Figure 5L). These 
findings suggest that the heterotypic clustering of KRasG12V and tH does not contribute to the 
anti-proliferative effect of n-3 PUFA.  Instead, our data support a mechanistic model in which 
activated KRas must be associated with a pool of PA in a cholesterol-poor domain of the 
membrane in order to recruit Raf and propagate signaling (Figure 6).  Further research is 
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required to elucidate how exogenous PA can reshape DHA modified KRas proteolipid 
complexes.  
 
 While cholesterol is the predominant sterol present in mammalian plasma membranes, 
ergosterol is the major sterol component present in lower eukaryotes such as Drosophila21.  
This suggests an evolutionary conserved aspect of membrane organization that even extends to 
the neural system18.  Therefore, our results using cholesterol-sensitive and insensitive Ras 
constructs are interpretable in the Drosophila ISC model (Figure 4C-E).  In this in vivo study, we 
also utilized a functionally active mutated form of Ras1 (RasV12). Interestingly, long chain n-3 
PUFA suppressed Ras1-dependent oncogenic signaling and phenotypes in the fly (Figure 4F-
H), similar to the murine model (Figure 1). We, therefore, posit that long-chain n-3 PUFA may 
also alter the nanoscale organization of Drosophila Ras1 proteolipid complexes, similar to 
mammalian KRas (Figure 6).  However, further work is needed to address this possibility.  
 
 In conclusion, our findings mechanistically link the reshaping of Ras proteolipid 
composition with the ability of n-3 PUFA to attenuate oncogenic Ras driven colonic 
hyperproliferation.  We propose that our novel observations support the feasibility of utilizing 
dietary strategies that target plasma membrane organization to reduce Ras oncogenic 
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Table 1.  Incorporation of exogenous fatty acids into Drosophila gut membrane 
phospholipids. 
Fatty Acid Holidic Control Fish Oil 
 (mol%) (mol%) 
14:0 4.62 3.07 
16:0 11.62 22.79 
16:1n-7 35.68 20.71 
18:0 3.36 3.47 
18:1n-9 36.77 32.19 
18:1n-7 0.00 1.94 
18:2n-6 (LA) 3.60 4.73 
20:0 3.28 1.77 
20:4n-6 0.46 0.00 
20:5n-3 (EPA) 0.00 5.47 
22:0 0.62 0.80 
22:6n-3 (DHA) 0.00 1.12 
Values represent means from pooled Drosophila guts (n=51 for Control, n=46 for Fish Oil), 
grown in two separate vials.  













Figure 1.  Dietary n-3 PUFA ameliorate oncogenic KRasG12D mediated colonic 
phenotypes. (A) Experimental design to determine the efficacy of dietary intervention on a 
genetic mouse model of oncogenic KRasG12D driven hyper-proliferation in the colon. (B) 
Isolated colonic crypt phospholipid profile from mice fed the experimental diets. (C) Alcian 
blue-staining of colonic crypts, including high magnification of crypts in dashed black box, with 
red dashed arrow representing crypt length.  (D) Nuclei (blue) and EdU-labeled (red) 
proliferating colonocytes in mice 4 weeks post tamoxifen (Tam, 200 mg/kg) fed corn or fish oil -
containing diets.  High magnification of crypts is shown in each dashed white box. 
Quantitative analysis of (E) crypt length and (F) cell proliferation. Scale bar = 50 µm. 
Statistical significance between treatments as indicated by different letters (P<0.05) was 
examined using one-way ANOVA and uncorrected Fisher’s LSD tests (Panel E; n = 4 mice 
per group and at least 508 crypts counted; Panel F; n = 4 mice per group and 200 crypts 














Figure 2.  Long chain n-3 PUFA disrupt Ras spatiotemporal dynamics.  Nanoclustering-
FRET analysis (illustrated in schemes) in (A) YAMC cells co-expressing GFP- and RFP-
tagged (B) truncated KRas (tK), (D) truncated HRas (tH), (F) tH-GFP and tK-RFP, or (H) full 
length oncogenic KRasG12V-GFP and tH-RFP. (A) Representative examples of FLIM-FRET 
images of YAMC cells from the different FRET samples as indicated. High magnification of 
cells is shown in each dashed white box.  (C, E, G and I) YAMC cells were treated with 
mevastatin (Mev, 5 µM) or indicated fatty acids (50 μM) for 24 or 72 h, respectively. Cells 
were transfected 48 h prior to imaging.  In all graphs (C, E, G, and I), the apparent FRET 
efficiency was calculated from FLIM data (mean ± SEM, n= 2-3 independent experiments).  
Values in the bars indicate the number of cells examined.  Statistical significance between 
treatments as indicated by different letters (P<0.05) was examined using one-way ANOVA 
and uncorrected Fisher’s LSD tests.  Un – untreated cells, LA – linoleic acid, EPA – 















Figure 3.  Long chain n-3 PUFA attenuate Ras mediated ERK signaling.  (A) SW48-
KRasG12D or (C) DKOB8 cells were grown in 8-well glass bottom dishes and treated with 50 
µM indicated fatty acid for 72 h.  (A) SW48-KRasG12D cells were serum starved (0% FBS) 
over the final 18 h in the presence of fatty acid and stimulated with EGF (25 ng/ml) for 5 min, 
then immediately fixed in ice cold 100% methanol. (C) DKOB8 cells were incubated with 
ponasterone A (10 μM) for the final 48 h, and were serum starved (0% FBS) over the final 18 
h in the presence of fatty acid and ponasterone A, then immediately fixed in ice cold 100% 
methanol.  Masked images of pERK (A) +/- EGF or (C) +/- ponasterone A.  Scale bar = 20 
µm. (B, D) Average fluorescence intensity for pERK.  Data represent average fluorescence 
intensity from at least 10 fields of view with ~10-30 cells per field, from 3 independent 
experiments.  (E) Representative immunofluorescence confocal images of DKOB8 cells 
stained for pERK (red) and nuclei (blue).  (F) Quantification of the ratio of fluorescence 
intensity of pERK in the nucleus vs cytoplasm.  Data represent average fluorescence intensity 
ratio of nucleus to cytoplasm for at least 90 cells, from 3 independent experiments.  Statistical 
significance between treatments as indicated by different letters (P<0.05) was examined using 
one-way ANOVA and uncorrected Fisher’s LSD tests.  Un – untreated cells, LA – linoleic acid, 











Figure 4.  Dietary n-3 PUFA disrupt Ras spatiotemporal dynamics, suppressing 
oncogenic Ras driven hyperproliferation phenotype and signaling in Drosophila 
midguts. (A) Schematic diagram of Drosophila intestine. (B) Representative intensity and 
lifetime field of view (FOV) images of Drosophila midguts.  Nanoclustering-FRET analysis 
(illustrated in schemes) in Drosophila midgut stem cells co-expressing GFP- and RFP-tagged 
(C) truncated K-Ras (tK), (D) truncated H-Ras (tH) or (E) tH-GFP and tK-RFP. (C, D, and E) 
1-2 d old Drosophila were placed on holidic diet containing no lipid (red) or fish oil (purple) for 
5 d prior to dissection and mounting of midguts for microscopy.  In all graphs (C, D and E), the 
apparent FRET efficiency was calculated from FLIM data (mean ± SEM, n=2 independent 
experiments).  Values in the bars indicate the number of analyzed FOVs.  Induction of 
oncogenic RasV12 in Drosophila midgut stem cells resulted in (F) hyperproliferation at 24 h 
and luminal thickening at 48 h.  Drosophila fed a fish oil vs control holidic diet for 5 d prior to 
induction of oncogenic RasV12 in midgut stem cells exhibited reduced hyperproliferation and 
midgut luminal thickening. (G) Quantitative analysis of proliferation as assessed by pH3 at 48 
h post RasV12 induction.  (H) After 24 h RasV12 induction, guts were harvested and used to 
assess pERK by western blot. Statistical significance between treatments as indicated by 












Figure 5. Long chain n-3 PUFA alter oncogenic KRasG12V proteolipid composition.  
Nanoclustering-FRET analysis (illustrated in scheme) in YAMC cells co-expressing full length 
oncogenic KRasG12V-GFP and (A) Raf-(R59A)-RBD-RFP, (E) LactC2-RFP, (G) Spo20-RFP, 
or (J) D4H-RFP.  YAMC cells were transfected with KRasG12V-GFP (Donor) alone or co-
transfected with indicated RFP tagged probe (Acceptor), and after 48 h fixed in 4% PFA. 
Where indicated, cells were untreated or treated with indicated fatty acid (50 μM) for 72 h and 
100 μM phosphatidic acid (PA, 18:0-18:1, Avanti #840861) or phosphatidylserine (PS, 18:0-
18:1, Avanti #840039) for 45 min prior to fixation.  Values in the bars indicate the number of 
cells examined.  (D) Representative examples of FLIM-FRET images of YAMC cells from the 
different FRET samples as indicated.  High magnification of cells is shown in each dashed 
white box.  Statistical significance between treatments as indicated by different letters 
(P<0.05) was examined using one-way ANOVA and uncorrected Fisher’s LSD tests. Un – 
untreated cells, LA – linoleic acid, EPA – eicosapentaenoic acid, DHA – docosahexaenoic 












Figure 6.  Summary diagram highlighting n-3 PUFA suppression of oncogenic Ras 
mediated signaling and hyperproliferation via disruption of Ras nanoscale proteolipid 
composition.  (A) Incorporation of long chain n-3 PUFA into colonocyte plasma membrane 
phospholipids mislocalizes oncogenic KRas from PA-rich domains into cholesterol-rich but 
PA-poor domains, generating heterotypic mixed clusters of tH and KRas proteins, thereby 
disrupting its ability as a nanoswitch to regulate ERK signaling.  This results in the 
suppression of oncogenic Ras-driven phenotypes in the colon. (B) Exogenous PA restores the 
lateral segregation of oncogenic KRas from cholesterol-rich domains and the recruitment of 
Raf.  
 
 






